eHIV Review

Long-acting injectable antiretroviral therapy is expected to improve adherence, reduce patient burden, and lower community viral load. But for which patients is it suitable? Can it be used as pre-exposure prophylaxis? How does the promise of long-acting ART actually mean in practice?</p><p>Join us for this <em>e</em>HIV Review podcast, as Dr. Tanyaporn Wansom, Senior Infectious Diseases Consultant at Chayun Consulting in Bangkok Thailand, takes us to the clinic to answer some of these key questionsTake ourpost-testto claim CME credits.To read a companion newsletterclick here.

Twenty percent of new HIV diagnoses occur among adolescents and young adults. They’re a populationunderserved by HIV prevention resources, with lower retention in HIV care. Their awareness and uptake of PrEP has been and remains low. What can their clinicians do to more effectively help these vulnerable young people?Join Dr. Luis Rubio from University of California San Francisco as we explore these and other important issues in thiseHIV Review podcast.Take ourpost-testto claim CME credits.To read a companion newsletterclick here.

Rapid ART — initiating ART as soon as possible after an HIV diagnosis: How effective is it at bringing people with newly diagnosed HIV into lasting care? When and how should it be initiated? Are there particular populations where attempting rapid ART should be avoided?Join us as we discuss these issues with Dr. Jonathan Colasanti from Atlanta’s Emory University and Grady Health System, in thiseHIV Review podcast.Take ourpost-testto claim CME credits.To read a companion newsletterclick here.

UndocumentedLatinX immigrants are a special population facing many difficulties that hinder their engagement in HIV careand prevention. One obvious barrier is language: manyundocumentedimmigrants do not understand either spoken or written English. Many may have neverreceived routine medical carebefore andcan bebaffled by the complexities of the medical system.Insurance status and financial concerns are additional barriers.Finally, HIV-related stigma and fear of disclosure of their HIV and/or immigration status can prevent undocumented Latinx immigrants from engaging in HIV care and prevention.How cancliniciansmost effectively help these individuals receive proper care? Join us as we find out, with Dr.Kathleen Page andnurse Owen Smith from Johns Hopkins University, in thiseHIVReview podcast.Take ourpost-testto claim CME credits.To read a companion newsletterclick here.

Better tolerability. More convenient dosing. Less serious side effects. Fewer potential drug-drug interactions. These are some of the most common reasonswhy individualsliving with HIV want or need to change their currently successful ART regimens.But what do clinicians need to consider when determining which ART to switch to? What role do the patient’s comorbidities play in the selection process? How do changes in the patient’s condition not related to HIV affect the safety and efficacy of their current regimen? What does the evidence say?Join usin thiseHIVReview podcastfor a case-based discussion withDr. Natasha Chida, from the Division of Infectious Diseasesat the Johns Hopkins University School of Medicine, about these increasingly important issues.Claim CME/CEU credit: Critical Factors When Switching ART | DKBmed

Do antivirals increaseweight gain?DoesPrEPreduce the effect of gender-affirming hormone therapy in transgender women?Joinus in the clinicwithDr. Sarah Puryear fromthe University of California San Francisco as we discuss these important questions.Take ourpost-testto claim CME credits.